Breaking news

Cisco Q1 Earnings Surge: Navigating Growth and AI Integration

by THEFUTURE.TEAM

November 13, 2025

Cisco (see more on Cisco) reported robust fiscal first-quarter performance with adjusted earnings per share of $1, surpassing the consensus estimate of 98 cents. Revenues reached $14.88 billion, slightly above the anticipated $14.77 billion, and marked an 8% increase from $13.84 billion year-over-year. The strong figures propelled Cisco’s stock upward by more than 7% in after-hours trading.

Performance Highlights And Business Segments

The company’s headline results include a net income jump to $2.86 billion compared to $2.71 billion a year ago. This quarter also represents Cisco’s fourth consecutive quarter of revenue growth following a period of consecutive year-over-year declines driven by broader economic uncertainties and postponements in government spending.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Cisco’s networking segment, the largest business unit, drove significant momentum with sales rising 15% to $7.77 billion—outperforming analyst expectations of $7.47 billion. In contrast, other key divisions experienced challenges: the security business revenue fell 2% to $1.98 billion (below the average estimate of $2.16 billion) and collaboration revenue declined 3% to $1.06 billion (just behind the expected $1.09 billion).

AI And Data Center Expansion

Recognizing the transformative potential of artificial intelligence, Cisco is intensifying its focus on AI-driven networking solutions. The company’s recent introduction of an Ethernet switch powered by Nvidia silicon underscores its strategy to align more closely with the AI boom. Notably, AI infrastructure orders from hyperscale customers reached an impressive $1.3 billion, a clear indicator of accelerated growth in data center spending primarily geared toward AI initiatives.

Forward-Looking Guidance And Strategic Initiatives

For fiscal second-quarter projections, Cisco anticipates revenues between $15 billion and $15.2 billion along with adjusted earnings per share ranging from $1.01 to $1.03, both figures exceeding average estimates. Full-year guidance projects revenues between $60.2 billion and $61 billion and earnings per share between $4.08 and $4.14, positioning the company favorably against analysts’ expectations.

CFO Mark Patterson emphasized the company’s strategic momentum: “Our relevance in AI continues to build. We have a multi-year, multi-billion-dollar campus refresh opportunity starting to ramp, with strong demand for our refreshed networking products.”

Market Impact And Future Outlook

The strong quarterly results come at a time when Cisco shares have surged 25% this year, outpacing the Nasdaq’s 21% growth. This financial uplift, driven predominantly by robust networking performance and AI-related investments, signals a renewed confidence in Cisco’s strategic direction and its ability to leverage emerging technologies.

With the company continuing to invest in innovation, its future roadmap appears well-positioned to capitalize on both traditional networking strengths and the expanding role of artificial intelligence in enterprise technology solutions.

For further insights, watch Cisco’s Product Chief Discussing AI Agents to understand how these advancements are shaping the industry.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.